References
- 1. Tanaka Y. Current concepts in the management of rheumatoid arthritis. Korean J Intern Med. 2016;31(2):210-8.
- 2. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016; (16)30173-8.
- 3. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36(3):182-8.
- 4. Sokka T, Kautiainen H, Pincus T, et al. Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther. 2010;12(2):R42.
- 5. Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316-22.
- 6. Banal F, Dougados M, Combescure C, Gossec L. Sensitivity and specificity of the American College of Rheumatology 1987 criteria for the diagnosis of rheumatoid arthritis according to disease duration: a systematic literature review and meta-analysis. Ann Rheum Dis. 2009;68(7):1184-91
- 7. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81.10.1002/art.27584
- 8. Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42(2):244-57
- 9. Bruce B, Fries JF. The Arthritis, Rheumatism and Aging Medical Information System (ARAMIS): still young at 30 years. Clin Exp Rheumatol. 2005;23(5Suppl 39): 163-7
- 10. Schett G, Stach C, Zwerina J, Voll R, Manger B. How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum. 2008;58(10):2936-4811.
- 11. Lopez-Olivo MA, Siddhanamatha HR, Shea B, Tugwell P, Wells GA, Suarez-Almazor ME. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev.2014 10;(6):CD000957.
- 12. Tree Age Pro. Healthcare software. Tree Age Software Inc [release 2005, 1998-2005]. Available from: www.softscout.com/software/healthcare-and-Human Services/Diagnosis
- 13. Kobelt G, Lindgren P, Singh A, Klareskog L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis. 2005;64(8):1174-9.
- 14. St. Clair EW, Pisetsky DS, Haynes BF. Rheumatoid arthritis. Philadelphia: Lippincott Williams & Wilkins; 2004.
- 15. Tariff book of health care services in health facilities of Republic of Serbia. Belgrade: Republic Institute for Health Insurance; 2008.
- 16. The World Bank. Data and Statistics. Available from: hptt://web.worldbank.org./wbsite/external/datastatistics/0. [updated 2010 September 12].
- 17. Drummond MF, Barbieri M, Wong JB. Analytic choices in economic models of treatments for rheumatoid arthritis: What makes a difference? Med Decis Making. 2005;25(5):520-33.10.1177/0272989X05280561
- 18. Weinstein MC, O’Brien B, Hornberger J, et al. ISPOR Task Force on Good Research Practices--Modeling Studies. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value Health. 2003;6(1):9-17
- 19. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793-806.10.1002/art.22025
- 20. Combe B, Codreanu C, Fiocco U, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. Ann Rheum Dis. 2009;68(7):1146-52
- 21. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88-96.
- 22. Nagy G, van Vollenhoven RF. Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now? Arthritis Res Ther. 2015;17:181.
- 23. Klareskog L, van der Heijde D, de Jager JP, et al. TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675-81.
- 24. Greenapple R. Trends in biologic therapies for rheumatoid arthritis: results from a survey of payers and providers. Am Health Drug Benefits. 2012;5(2):83-92.
- 25. Howe A, Eyck LT, Dufour R, Shah N, Harrison DJ. Treatment patterns and annualdrug costs of biologic therapies across indications from the Humana commercial database. J Manag Care Spec Pharm. 2014;20(12):1236-44.
- 26. Lambert CM. Medical therapy for rheumatoid arthritis--value for money? Rheumatology (Oxford). 2001;40(9):961-4.10.1093/rheumatology/40.9.961
- 27. Kobelt G, Kasteng F. Access to innvative treatments in rheumatoid arthritis in Europe. A report prepared for the Europian Federation of Pharmaceutical Industry Associations (EFPIA); 2009
- 28. Joensuu JT, Huoponen S, Aaltonen KJ, Konttinen YT, Nordström D, Blom M. The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review. PLoS One. 2015;10(3):e0119683.